Sickle cell disease (SCD), the most common inherited hemoglobin disorder in the U.S., affects nearly 100,000 people. Yet progress for advancing curative treatments such as hematopoietic cell transplantation (HCT) has been limited in part due to the shortage of clinical trial (CT) participation by individuals most affected. How to improve clinical trial participation for patients is the $1 million dollar question for many healthcare providers. Participants attending this session will be able to identify evidence-based strategies to enhance patients’ trust and increase HCT CT participation.
- Creating a Pediatric Hematology/Oncology Manuscript to Submit for Publication in a Nursing Journal (003)
- Opening Keynote: Never Ever Give Up! (101)
- General Session: Oral Medicine for Pediatric Hematology/Oncology Nursing (102)
- Going Viral: Review of Viral Illness and Antiviral Therapy in Hematopoietic Stem Cell Transplant Pediatric Patients (200)
- Management of Retinoblastoma in 2018: A Nursing Perspective (201)